Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2017
Materias:	diabetes mellitus insulinotherapy insulin detemir liraglutide Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/3e6b1c403d2245b08a42415262fb3420
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e6b1c403d2245b08a42415262fb3420
record_format	dspace
spelling	oai:doaj.org-article:3e6b1c403d2245b08a42415262fb34202021-11-14T09:00:21ZCombined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance2072-03512072-037810.14341/7875https://doaj.org/article/3e6b1c403d2245b08a42415262fb34202017-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8296https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analogue) with liraglutide (GLP-1 analogue) reduces fasting and postprandial glycaemia, lowers the risk of hypoglycaemia and does not have a negative impact on body weight. In this literature review, the pharmacodynamic and pharmacokinetic profiles, as well as the potential benefits of combined insulin detemir and liraglutide therapy on diabetic nephropathy and high cardiovascular disease risk were determined. Data from randomised clinical trials and the National Registry were used to assess the clinical efficacy of combined insulin detemir and liraglutide therapy. The different mechanistic actions of insulin detemir and liraglutide resulted in an additive glucose-lowering effect, which did not affect the pharmacodynamic and pharmacokinetic profiles of each therapeutic agent.Lyudmila Alexandrovna RuyatkinaMaxim SorokinEndocrinology Research Centrearticlediabetes mellitusinsulinotherapyinsulin detemirliraglutideNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 2, Pp 142-150 (2017)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus insulinotherapy insulin detemir liraglutide Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus insulinotherapy insulin detemir liraglutide Nutritional diseases. Deficiency diseases RC620-627 Lyudmila Alexandrovna Ruyatkina Maxim Sorokin Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
description	Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analogue) with liraglutide (GLP-1 analogue) reduces fasting and postprandial glycaemia, lowers the risk of hypoglycaemia and does not have a negative impact on body weight. In this literature review, the pharmacodynamic and pharmacokinetic profiles, as well as the potential benefits of combined insulin detemir and liraglutide therapy on diabetic nephropathy and high cardiovascular disease risk were determined. Data from randomised clinical trials and the National Registry were used to assess the clinical efficacy of combined insulin detemir and liraglutide therapy. The different mechanistic actions of insulin detemir and liraglutide resulted in an additive glucose-lowering effect, which did not affect the pharmacodynamic and pharmacokinetic profiles of each therapeutic agent.
format	article
author	Lyudmila Alexandrovna Ruyatkina Maxim Sorokin
author_facet	Lyudmila Alexandrovna Ruyatkina Maxim Sorokin
author_sort	Lyudmila Alexandrovna Ruyatkina
title	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
title_short	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
title_full	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
title_fullStr	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
title_full_unstemmed	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
title_sort	combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
publisher	Endocrinology Research Centre
publishDate	2017
url	https://doaj.org/article/3e6b1c403d2245b08a42415262fb3420
work_keys_str_mv	AT lyudmilaalexandrovnaruyatkina combinedinsulindetemirandliraglutidetherapyintype2diabeticpatientsabaseforanalliance AT maximsorokin combinedinsulindetemirandliraglutidetherapyintype2diabeticpatientsabaseforanalliance
_version_	1718429519740665856

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

Ejemplares similares